WEBULL
WebtradeDownload

Combination Cancer Trial Might Change The Case For Investing In Biohaven Stock (BHVN)

Simply Wall St · 3d ago
  • Biohaven announced that it entered a clinical supply agreement with Regeneron to test BHV-1530 in combination with cemiplimab in patients with solid tumors, with enrollment into the new combination cohort already underway and building on an existing supply partnership around BHV-1510.
  • The expanded collaboration signals that Biohaven sees enough scientific rationale and operational value in pairing its oncology assets with Regeneron’s Anti-PD-1 therapy to justify additional trial complexity and cost.
  • We will examine how Biohaven’s investment narrative is influenced by the deeper Regeneron partnership around BHV-1530 combination development.

Scan how Biohaven’s oncology push with Regeneron compares with other potential breakouts in cancer and biotech by reviewing the hand picked 19 high quality undiscovered gems shaping the next wave of treatments.

What Is Biohaven's Investment Narrative?

To own Biohaven stock, you have to buy into a high burn, high option value story. The business today has essentially no revenue, a market value around US$1.96b, and a pipeline spread across neurology, immunology, metabolic disease, and now a deeper oncology tie up with Regeneron. The cemiplimab combination around BHV-1530 fits that big picture. It leans into partnerships instead of going it alone, which can ease trial execution and drug supply but does not change the near term fact that the company remains loss making with no commercial engine.

The practical question is whether upcoming clinical readouts and partnering decisions arrive before the balance sheet bites. Biohaven has less than one year of cash runway and has already diluted holders, which lines up with the share price falling roughly 23% over 30 days and about 27% over 90 days. The Regeneron expansion may help on the science and execution side. It does not by itself solve funding, pricing power, or the pressure that comes from an expensive P/B of 149.3x versus biotech peers while still being unprofitable.

That said, the real tension in the Biohaven story shows up once you consider ...

There's only one way to know the right time to buy, sell or hold Biohaven. Head to Simply Wall St's company report for the latest analysis of Biohaven's Fair Value.

NYSE:BHVN 1-Year Stock Price Chart
NYSE:BHVN 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the most optimistic analysts see the Regeneron link as a possible springboard for Biohaven. Before this supply deal, the highest forecasts already penciled in revenue of about US$285.1m and earnings of roughly US$49.2m by 2029. That is a far more upbeat path than consensus, and this new oncology combo could reshape those views again.

Explore another Biohaven fair value estimate, including one that suggests as much as 472% upside from the current price!

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Biohaven?

If Biohaven has you thinking about where asymmetric outcomes might sit in your portfolio, it can help to widen the search across different styles of opportunity using the Simply Wall St Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.